Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman(Cancer Research Center), Kwok‐Kin Wong(NYU Langone Health), Samanthi A. Perera(Dana-Farber/Harvard Cancer Center), Robert F. Padera(Brigham and Women's Hospital), Rabi Upadhyay(NYU Langone Health), Alexander R. Guimarães(Harvard University Press), Jessica Simendinger(Cell Signaling Technology (United States)), Lewis C. Cantley(Harvard University), Umar Mahmood(Athinoula A. Martinos Center for Biomedical Imaging), Ralph Weissleder(Massachusetts General Hospital), Angela Lightbown(Cell Signaling Technology (United States)), Lucian R. Chirieac(Mount Sinai Hospital), Liang Chen(Henan Medical University), Xiaohong Tan(Beijing Proteome Research Center), Katherine Crosby(Cell Signaling Technology (United States)), Kate McNamara(Dana-Farber/Harvard Cancer Center), Ramneet Kaur(Massachusetts General Hospital), Michel Maira(Novartis Institutes for BioMedical Research), Carlos Garcı́a-Echeverrı́a(Novartis Institutes for BioMedical Research), Timothy Li(Beth Israel Deaconess Medical Center), Youngchul Song(Beth Israel Deaconess Medical Center)
Cited by 1,330
Related Papers
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
A clearer vision for in vivo imaging
|Nature Biotechnology|2001|3.8k
Imaging in the era of molecular oncology
|Nature|2008|2.3k